Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

By News Health
37 minutes Ago

(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and pertuzumab (Perjeta) maintenance…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcsvideopearls/119134

Author :

Publish date : 2025-12-22 17:56:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

Polatuzumab-Based Combination Continues to Impress in Real-World DLBCL Analyses

Sniffing Out the Optimal Radiation Dose for Head and Neck Cancer

Fellow Nurses: Did You (or Will You) Go to Your Staff Christmas Party?

Cheddar Cheese Recalled; Nick Reiner's Medication Change; How Safe Is U.S. Food?

Novel Treatment Combo Ups Survival in Multiple Myeloma